This article is more than 5 years old. Information may no longer be current.
TFS acquires German dermatology specialist SCIderm
Click Here to Manage Email Alerts
TFS International has acquired German dermatology specialist SCIderm GmbH, according to a press release.
The companies had entered a strategic partnership in 2014 to combine resources and scientific expertise within dermatology development, according to the release. TFS will reach 350 investigational sites in Europe and North American with the acquisition, according to the release.
“For the first time, the merger will give us the opportunity to take our unique knowledge in dermatology to a global level,” Kristian Reich, MD, professor of dermatology at the Georg-August-University Göttingen and inflammation specialist at the Dermatologikum Hamburg in Germany, and a SCIderm shareholder, stated in the release. Reich will become a strategic scientific adviser at TFS with acquisition
“This is important because we have seen the bars for clinical development in dermatology and chronic inflammatory diseases significantly rising over recent years with later strategic advantages in a highly competitive environment depending on early expert decision in study design and selection,” Reich stated in the release.
Since 2014, the two companies have managed 63 global clinical trials in dermatology, with more than 17,000 patients in 18 indications, according to the release.
TFS International was founded in Sweden and operates from 25 locations throughout Europe and North America. SCIderm is headquartered in Hamburg, Germany.
Reference: www.tfscro.com